Therapeutic Uses of Traditional Chinese Medicines Against COVID-19

References

• Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135. doi:10.3390/v12020135
   PubMed Web of Science ®Google Scholar
• Yu X, Li N, Dong Y. Observation on China’s Strategies to prevent the resurgence of the COVID-19 epidemic. Risk Manag Healthc Policy. 2021;14:2011–2019. doi:10.2147/RMHP.S30541334040464
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO director-general’s remarks at the media briefing on 2019-nCoV on 11 February 2020; 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-The-media-briefing-on-2019-ncov-on-11-february-2020. Accessed November 5, 2021.
   Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020;382:1708–1720. doi:10.1056/NEJMoa200203232109013
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-531986264
   PubMed Web of Science ®Google Scholar
• World Health Organization. Situation report-29; 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200218-sitrep-29-covid-19.pdf?sfvrsn=6262de9e_2. Accessed November 5, 2021.
   Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-732007143
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;588:E6–E6. doi:10.1038/s41586-020-2951-z33199918
   PubMed Web of Science ®Google Scholar
• Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15:327–347.26868298
   PubMed Web of Science ®Google Scholar
• Li T, Peng T. Traditional Chinese herbal medicine as a source of molecules with antiviral activity. Antiviral Res. 2013;97:1–9. doi:10.1016/j.antiviral.2012.10.00623153834
   PubMed Web of Science ®Google Scholar
• Leung PC. The efficacy of Chinese medicine for SARS: a review of Chinese publications after the crisis. Am J Chin Med. 2007;35:575–581. doi:10.1142/S0192415X0700507717708624
   PubMed Web of Science ®Google Scholar
• Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7:4.32029004
   PubMed Web of Science ®Google Scholar
• Habibzadeh P, Stoneman EK. The novel coronavirus: a bird’s eye view. Int J Occup Environ Med. 2020;11:65–71. doi:10.15171/ijoem.2020.192132020915
   PubMed Web of Science ®Google Scholar
• Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother. 2018;26:2040206618764483. doi:10.1177/204020661876448329562753
   PubMedGoogle Scholar
• De Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infectionS. Chem Asian J. 2019;14:3962–3968. doi:10.1002/asia.20190084131389664
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271.32020029
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9. doi:10.1126/scitranslmed.aal3653
   Web of Science ®Google Scholar
• Zhang L, Liu Y. Potential interventions for novel coronavirus in china: a systemic review. J Med Virol. 2020;92:479–490.32052466
   PubMed Web of Science ®Google Scholar
• Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. doi:10.1056/NEJMoa200119132004427
   PubMed Web of Science ®Google Scholar
• Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6:67–69. doi:10.1016/S1473-3099(06)70361-916439323
   PubMed Web of Science ®Google Scholar
• Li G, De Clercq E, Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19:149–150. doi:10.1038/d41573-020-00016-032127666
   PubMed Web of Science ®Google Scholar
• Faure E, Poissy J, Goffard A, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One. 2014;9:e88716. doi:10.1371/journal.pone.008871624551142
   PubMed Web of Science ®Google Scholar
• Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924. doi:10.1016/j.ijantimicag.2020.10592432081636
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343. doi:10.1371/journal.pmed.003034316968120
   PubMed Web of Science ®Google Scholar
• World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (‎2019-nCoV)‎ infection is suspected: interim guidance, 28 January 2020; 2020. Available from: https://apps.who.int/iris/handle/10665/330893. Accessed November 23, 2021.
   Google Scholar
• Hung IFN, To KKW, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144:464–473. doi:10.1378/chest.12-290723450336
   PubMed Web of Science ®Google Scholar
• Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–76.32112977
   PubMed Web of Science ®Google Scholar
• Tsang KWT. Severe acute respiratory syndrome. Nat Med. 2005;4:95–106.
   Google Scholar
• Chen Z, Nakamura T. Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS. Phytother Res. 2004;18:592–594. doi:10.1002/ptr.148515305324
   PubMed Web of Science ®Google Scholar
• Lau TF, Leung PC, Wong ELY, et al. Using herbal medicine as a means of prevention experience during the SARS crisis. Am J Chin Med. 2005;33:345–356. doi:10.1142/S0192415X0500296516047553
   PubMed Web of Science ®Google Scholar
• Hsu CH, Hwang KC, Chao CL, et al. Can herbal medicine assist against avian flu? Learning from the experience of using supplementary treatment with Chinese medicine on SARS or SARS-like infectious disease in 2003. J Altern Complement Med. 2006;12:505–506. doi:10.1089/acm.2006.12.50516884338
   PubMed Web of Science ®Google Scholar
• Cinatl J, Morgenstern B, Bauer G, et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045–2046. doi:10.1016/S0140-6736(03)13615-X12814717
   PubMed Web of Science ®Google Scholar
• Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31:69–75. doi:10.1016/j.jcv.2004.03.00315288617
   PubMed Web of Science ®Google Scholar
• Wang SQ, Du QS, Zhao K, et al. Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy. Amino Acids. 2007;33:129–135. doi:10.1007/s00726-006-0403-116998715
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang M, He L, Li Y. Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS). Cochrane Database Syst Rev. 2012;10:Cd004882.23076910
   PubMed Web of Science ®Google Scholar
• Wu T, Yang X, Zeng X, Poole P. Traditional Chinese medicine in the treatment of acute respiratory tract infections. Resp Med. 2008;102:1093–1098. doi:10.1016/j.rmed.2008.03.015
   Web of Science ®Google Scholar
• Liu LS, Lei N, Lin Q, et al. The effects and mechanism of yinqiao powder on upper respiratory tract infection. Int J Biotechnol Wellness Ind. 2015;4:57–60. doi:10.6000/1927-3037.2015.04.02.2
   Google Scholar
• Gao J, Li J, Shao X, et al. Antiinflammatory and immunoregulatory effects of total glucosides of Yupingfeng powder. Chin Med J (Engl). 2009;122:1636–1641.19719964
   PubMed Web of Science ®Google Scholar
• Dong L, Xia JW, Gong Y, et al. Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease. Evid Based Complement Alternat Med. 2014;2014(1–11):80. doi:10.1155/2014/637969
   Web of Science ®Google Scholar
• Gao Y, Fang L, Cai R, et al. Shuang-Huang-Lian exerts anti-inflammatory and anti-oxidative activities in lipopolysaccharide stimulated murine alveolar macrophages. Phytomedicine. 2014;21:461–469. doi:10.1016/j.phymed.2013.09.02224192210
   PubMed Web of Science ®Google Scholar
• Xiao GL, Song K, Yuan CJ. A literature reports on the treatment of SARS by stages with traditional Chinese medicine. J Emerg Chin Med Hunan. 2005;4:53–55.
   Google Scholar
• Yu MS, Lee J, Lee JM, et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg Med Chem Lett. 2012;22:4049–4054. doi:10.1016/j.bmcl.2012.04.08122578462
   PubMed Web of Science ®Google Scholar
• Fung KP, Leung PC, Tsui KW, et al. Immunomodulatory activities of the herbal formula Kwan Du Bu Fei Dang in healthy subjects: a randomised, double-blind, placebo-controlled study. Hong Kong Med J. 2011;17(Suppl 2):41–43.
   Google Scholar
• Wu CY, Jan JT, Ma SH, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004;101:10012–10017. doi:10.1073/pnas.040359610115226499
   PubMed Web of Science ®Google Scholar
• Kuhn JH, Radoshitzky SR, Li W, et al. The SARS Coronavirus receptor ACE 2 A potential target for antiviral therapy. In: Holzenburg A, Bogner E, editors. New Concepts of Antiviral Therapy. Boston, MA: Springer US; 2006:397–418.
   Google Scholar
• Ho T, Wu S, Chen J, Li C, Hsiang C. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007;74:92–101. doi:10.1016/j.antiviral.2006.04.01416730806
   PubMed Web of Science ®Google Scholar
• Wang W, Ma X, Han J, et al. Neuroprotective effect of scutellarin on ischemic cerebral injury by down-regulating the expression of angiotensin-converting enzyme and AT1 receptor. PLoS One. 2016;11:e0146197. doi:10.1371/journal.pone.014619726730961
   PubMed Web of Science ®Google Scholar
• Deng YF, Aluko RE, Jin Q, Zhang Y, Yuan LJ. Inhibitory activities of baicalin against renin and angiotensin-converting enzyme. Pharm Biol. 2012;50:401–406. doi:10.3109/13880209.2011.60807622136493
   PubMed Web of Science ®Google Scholar
• Yi L, Li Z, Yuan K, et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol. 2004;78:11334–11339. doi:10.1128/JVI.78.20.11334-11339.200415452254
   PubMed Web of Science ®Google Scholar
• Schwarz S, Wang K, Yu WJ, Sun B, Schwarz W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Res. 2011;90:64–69. doi:10.1016/j.antiviral.2011.02.00821356245
   PubMed Web of Science ®Google Scholar
• Schwarz S, Sauter D, Wang K, et al. Kaempferol derivatives as antiviral drugs against the 3a channel protein of Coronavirus. Planta Med. 2014;80:177–182. doi:10.1055/s-0033-136027724458263
   PubMed Web of Science ®Google Scholar
• Cheng PW, Ng LT, Chiang LC, Lin CC. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin Exp Pharmacol Physiol. 2006;33:612–616. doi:10.1111/j.1440-1681.2006.04415.x16789928
   PubMed Web of Science ®Google Scholar
• Chen CJ, Michaelis M, Hsu HK, et al. Toona sinensis Roem tender leaf extract inhibits SARS coronavirus replication. J Ethnopharmacol. 2008;120:108–111.18762235
   PubMed Web of Science ®Google Scholar
• Ryu YB, Park SJ, Kim YM, et al. SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii. Bioorg Med Chem Lett. 2010;20:1873–1876. doi:10.1016/j.bmcl.2010.01.15220167482
   PubMed Web of Science ®Google Scholar
• Ryu YB, Jeong HJ, Kim JH, et al. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition. Bioorg Med Chem. 2010;18:7940–7947. doi:10.1016/j.bmc.2010.09.03520934345
   PubMed Web of Science ®Google Scholar
• Schmidtke M, Meier C, Schacke M, et al. Antiviral activity of phenolic polymers and cycloSal-pronucleotides against a SARS-associated coronavirus. Chemother J. 2005;14:16–21.
   Google Scholar
• Chen LR, Wang YC, Lin YW, et al. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. Bioorg Med Chem Lett. 2005;15:3058–3062. doi:10.1016/j.bmcl.2005.04.02715896959
   PubMed Web of Science ®Google Scholar
• van de Sand L, Bormann M, Alt M, et al. Glycyrrhizin effectively inhibits SARS-CoV-2 replication by inhibiting the viral main protease. Viruses. 2021;13(4):609. doi:10.3390/v1304060933918301
   PubMed Web of Science ®Google Scholar
• Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71. doi:10.5582/bst.2020.0102031996494
   PubMed Web of Science ®Google Scholar
• Science CAo. Researchers in Shanghai Institute of Drugs and Wuhan Virus Institute discovered that the Chinese patent medicine Shuanghuanglian oral liquid can inhibit the 2019-new coronavirus; 2020.
   Google Scholar
• Chen X, Howard OM, Yang X, Wang L, Oppenheim JJ, Krakauer T. Effects of Shuanghuanglian and Qingkailing, two multi-components of traditional Chinese medicinal preparations, on human leukocyte function. Life Sci. 2002;70:2897–2913. doi:10.1016/S0024-3205(02)01541-212269401
   PubMed Web of Science ®Google Scholar
• Chan MC, Chan RW, Mok CK, Mak NK, Wong RN. Indirubin-3ʹ-oxime as an antiviral and immunomodulatory agent in treatment of severe human influenza virus infection. Hong Kong Med J. 2018;24(Suppl 6):45–47.
   Google Scholar
• Ding Y, Zeng L, Li R, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017;17:130. doi:10.1186/s12906-017-1585-728235408
   PubMed Web of Science ®Google Scholar
• Poon PM, Wong CK, Fung KP, et al. Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self-control study. Am J Chin Med. 2006;34:13–21. doi:10.1142/S0192415X0600359X16437735
   PubMed Web of Science ®Google Scholar
• Li S, Chen C, Zhang H, et al. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res. 2005;67:18–23. doi:10.1016/j.antiviral.2005.02.00715885816
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Transcript of press conference in 17, February, 2020; 2020. Available from: http://www.nhc.gov.cn/xcs/s3574/202002/f12a62d10c2a48c6895cedf2faea6e1f.shtml. Accessed November 8, 2021.
   Google Scholar
• National Health Commission of the People’s Republic of China. Notice on the issunance of guidelines of diagnosis and treatment for 2019-nCoV infected pneumonia (version 6). 6 ed; 2020. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml?from=timeline. Accessed November 8, 2021.
   Google Scholar
• Han YY, Zhao MR, Shi B, et al. Application of integrative medicine protocols on treatment of coronavirus disease 2019. Chi Tradit Herbal Drugs. 2020;1–5:878–882.
   Google Scholar
• Zhu YG, Deng ZW, Liu LH, et al. Compilation of drug information for the diagnosis and treatment of COVID-19 (version 1). Cent South Pharm. 2020;31–14.
   Google Scholar
• Luo H, Tang QL, Shang YX, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med. 2020;26(4):243–250. doi:10.1007/s11655-020-3192-632065348
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang Y, Li X, Li XX. Analysis on prevention plan of Corona virus disease-19 (COVID-19) by traditional Chinese medicine in various regions. Chin Herb Med. 2020;34:1–7.
   Google Scholar
• Zhao J, Tian SS, Yang J, Liu J, Zhang WD. Investigating the mechanism of Qing-Fei-Pai-Du-Tang for the treatment of Novel Coronavirus Pneumonia by network pharmacology. Chin Herb Med. 2020;3:1–7.
   Google Scholar
• Yao KT, Liu MY, Li X, Huang JH, Cai HB. Retrospective clinical analysis on treatment of novel coronavirus-infected pneumonia with traditional Chinese Medicine Lianhua Qingwen. Chin J Exp Tradit Med Form. 2020;45:1–7.
   Google Scholar
• Lu RB, Wang WJ, Li X. Treatment of suspected new coronavirus pneumonia with Chinese medicine Lianhua Qingwen Clinical observation of 63 suspected cases. J Tradit Chin Med. 2020;3:1–5.
   Google Scholar
• Zhang JW, Hu X, Jin PF. Cytokine storms caused by 2019-nCoV and drug therapy. Chin Pharm J. 2020;96:1–9.
   Google Scholar
• Wang J, Qiao LF, Li YS, Yang GT. Shen Fu injection activate the macrophage NF-kB of rats’ alveolar induced by LPS. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong. 2009;1:15–18.
   Google Scholar
• Chang XJ, Xiao W, Zhang S, et al. Mechanism of Re Du Ning injection on anti-acute lung injury in rats based on cytokines storm. Chin Herb Med. 2014;46:236–239.
   Google Scholar
• Zou HM, He TZ, Chen X. Tetrandrine inhibits differentiation of proinflammatory subsets of T helper cells but spares de novo differentiation of iTreg cells. Int Immunopharmacol. 2019;69:307–312. doi:10.1016/j.intimp.2019.01.04030769211
   PubMed Web of Science ®Google Scholar
• Chen H, Du Q. Potential natural compounds for preventing 2019-nCoV infection. Preprints. 2020. doi:10.20944/preprints2020001.0358
   Google Scholar
• Zhang F, Huang J, Liu W, et al. Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: implication of herb-drug interactions in COVID-19 pharmacotherapy. Food Chem Toxicol. 2021;149:111998. doi:10.1016/j.fct.2021.11199833476691
   PubMed Web of Science ®Google Scholar
• Zhao J, Tian S, Lu D, et al. Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19. Phytomedicine. 2021;85:153315. doi:10.1016/j.phymed.2020.15331532978039
   PubMed Web of Science ®Google Scholar
• Yu S, Zhu Y, Xu J, et al. Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2. Phytomedicine. 2021;85:153364. doi:10.1016/j.phymed.2020.15336433041173
   PubMed Web of Science ®Google Scholar
• Huang YF, Bai C, He F, Xie Y, Zhou H. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19). Pharmacol Res. 2020;158:104939. doi:10.1016/j.phrs.2020.10493932445956
   PubMed Web of Science ®Google Scholar